Aldeyra seeks NDA approval for dry eye disease treatment in US

Aldeyra Therapeutics has submitted a new drug application (NDA) to the US FDA for topical ocular reproxalap, to treat signs and symptoms of dry eye disease.

Related Keywords

Todd Brady , ,Larsson Syndrome ,